Bangkok Genomics Innovation Public Company LimitedSET: BKGI🇹🇭 TH

Internal Control · 2025

Internal Control — Board Opinion

Summary of the Board's Opinion on Internal Control

The Board of Directors has assessed the adequacy of the Company’s internal control system by considering the internal control evaluation form in accordance with the guidelines of the Office of the Securities and Exchange Commission (SEC), together with inquiries made with the management and the review of relevant reports, in order to ensure that the Company has an appropriate and adequate internal control system for its business operations.

Such assessment is based on the framework of the Committee of Sponsoring Organizations of the Treadway Commission (COSO), which comprises five key components as follows:

  • Control Environment

  • Risk Assessment

  • Control Activities

  • Information and Communication

  • Monitoring Activities

The Board of Directors is of the opinion that the Company has an adequate and appropriate internal control system for its business operations. The Company has established an appropriate organizational structure, systems, and sufficient personnel to effectively implement such internal control system. This supports the Company’s operations in accordance with good corporate governance principles, ensuring transparency and accountability.

In addition, the Company has established continuous monitoring and evaluation processes to ensure that its assets are safeguarded against unauthorized or improper use. The Company also has appropriate control measures in place for transactions that may give rise to conflicts of interest, including connected transactions, to ensure compliance with applicable laws and regulations.

In this regard, the Board of Directors has not identified any material weaknesses in the Company’s internal control system.

Adequacy & Appropriateness of the Internal Control System

Internal Control Framework Used

FrameworkDetail
The Committee of Sponsoring Organizations of the Treadway Commission (COSO)

The company has considered and assessed the adequacy of its internal control system based on the internal control adequacy evaluation framework of the Securities and Exchange Commission (SEC). Additionally, the company has conducted inquiries with management to evaluate the internal control system across various aspects, following the guidelines of The Committee of Sponsoring Organizations of the Treadway Commission ("COSO"), which includes the following:

1. Control Environment

2. Risk Assessment

3. Control Activities

4. Information and Communication

5. Monitoring Activities

Internal Control Deficiencies

Number of Deficiencies

MetricCurrent YearPrevious YearTwo Years Ago
Total number of internal control system deficiencies (cases)000

Audit Committee & Auditor Observations

Audit Committee's Opinion Differs from the Board's

No

Auditor Has Observations on Internal Control

No

Opinion on the Head of Internal Audit

Head of Internal Audit

3160

Audit Committee's Opinion on the Head of Internal Audit

At the Audit Committee meeting on February 14, 2024, the committee resolved to appoint P&L Internal Audit Co., Ltd. and P&L IT Audit Co., Ltd. as the company's internal auditors for the year 2024. These two companies designated Ms. Wannawimon Jongsuriyaphas, an executive director, as the primary person responsible for conducting the company's internal audit operations.

The Audit Committee reviewed the qualifications of both companies and Ms. Wannawimon Jongsuriyaphas and found them highly suitable for the role. The evaluation was based on key factors, including independence in performing duties, extensive experience in internal auditing, as well as relevant professional training and certifications, such as the Internal Auditing Certificate Program (IACP) from the Federation of Accounting Professions under the Royal Patronage of His Majesty the King and the Certified Professional Internal Auditor of Thailand (CPIAT) from the Institute of Internal Auditors of Thailand (IIAT).

Additionally, the committee resolved that any appointment, dismissal, or transfer of the head of the internal audit unit must receive approval or endorsement from the Audit Committee. Further details regarding the qualifications of the internal audit head are provided in Enclosure 3.

Appointment, Discharge & Transfer of the Head of Internal Audit

Requires Audit Committee Approval

Yes

Description

The Audit Committee is responsible for overseeing that the Company has an effective and independent internal audit function. The guidelines for considering the appointment of the internal auditor are as follows:

1.Qualifications and Independence

The Audit Committee shall consider the qualifications of the internal auditor to ensure that he/she possesses appropriate knowledge, competence, and experience, and is able to perform duties independently without any conflict of interest with the Company.

2..Recruitment and Selection Process

The recruitment of the internal auditor may be carried out through the appointment of internal personnel or the engagement of an external service provider. The Audit Committee shall consider the appropriateness of the Company’s organizational structure, business size, and operational complexity.

3..Appointment, Transfer, and Termination

The Audit Committee has the authority to approve the appointment, transfer, or termination of the Head of Internal Audit to ensure independence and freedom from management influence.

4.Scope of Duties and Responsibilities

The Audit Committee shall define and review the scope of duties and responsibilities of the internal audit function to ensure coverage of internal control systems, risk management, and good corporate governance.

5.Reporting and Oversight

The internal auditor shall report audit results directly to the Audit Committee on a regular basis and shall have the authority to meet with the Audit Committee independently to report significant matters without management presence.

6.Performance Evaluation

The Audit Committee shall regularly evaluate the performance of the internal auditor to ensure that the internal audit function operates effectively, complies with professional standards, and supports the Company’s corporate governance.

Related Party Transactions

Has Related Party Transactions

Yes

Counterparties & Transactions

Monetary Unit

1000000

Counterparties with Potential Conflicts

NamePerson / Juristic PersonType of BusinessNature of RelationshipAs of Date (YYYY-MM-DD)
BGI Health (Hong Kong) Co.,LtdJuristic PersonGenetic testing services, including research and development in physical and commercial biotechnology

• Shareholders (holding 37.40 percent of the company's shares)

• 100.00% owned by BGI Genomics Co., Ltd

2025-12-31T00:00
BGI Tech Solutions (Hong Kong) Company LimitedJuristic PersonGenetic testing services, including research and development in physical and commercial biotechnology

• Joint shareholder (shares held by BGI Health (HK) Co., Ltd.)

2025-12-31T00:00
BGI Health (AU) Co.,LtdJuristic PersonGenetic testing services, including research and development in physical and commercial biotechnology

• Joint shareholder (shares held by BGI Health (HK) Co., Ltd.)

2025-12-31T00:00
Thai Omics Company LimitedJuristic PersonProvision of services related to genomic medicine

• Joint directors

2025-12-31T00:00
MGI Tech Singapore Pte. Ltd.Juristic PersonGenetic testing services, including research and development in physical and commercial biotechnology

• Common shareholder (Mr. Wang Jian, who is the Ultimate Shareholder as well as the Company, holds shares indirectly)

2025-12-31T00:00
Krung Thai Tractor Company LimitedJuristic PersonSale of tractors, hydraulic excavators, wheel loaders, air compressors and various spare parts

• Shareholders are individuals who have a relationship with the company's directors.

2025-12-31T00:00
Shenzhen Zaozhidao Technology Co.,Ltd.Juristic PersonTechnological technique development

• Common shareholder (shares held by BGI Genomics Co., Ltd)

2025-12-31T00:00
BGI Bio Solutions (Hong Kong) Co., Ltd.Juristic PersonAnalytical services, genetics, and commercial physical and biological research and development

• Common shareholder (shares held indirectly by BGI Genomics Co., Ltd.)

2025-12-31T00:00
Omicsphere Company LimitedJuristic PersonDistributor of scientific medical device, equipment and chemicals used in laboratories.

• SUBSIDIARIES

2025-12-31T00:00
Comprehensive Care LimitedJuristic PersonBusiness related to medical technology, advanced medical products, and-related equipment

• SUBSIDIARIES

2025-12-31T00:00
Biovision Tech Company LimitedJuristic PersonOperate as a consultancy service provider for businesses.

• Subsidiaries

2025-12-31T00:00
BGI Health (Hungary) Co.,LtdJuristic PersonGenetic testing services, including research and development in physical and commercial biotechnology

• Joint shareholder (shares held by BGI Health (HK) Co., Ltd.)

2025-12-31T00:00
BGI Genomics UK LimitedJuristic PersonGenetic testing services, including research and development in physical and commercial biotechnology

• Joint shareholders (shares held by BGI Genomics Co., Ltd. indirectly)

2025-12-31T00:00
Krung Thai Land Development Company LimitedJuristic PersonReal Estate Development

• Joint director

2025-12-31T00:00
Genovation Co., Ltd.Juristic PersonHealth Analytics Management, Health Check

• Joint directors

2025-12-31T00:00
Pure Select Company LimitedJuristic PersonEstablish a retail store selling pharmaceutical and medical supplies

• Joint director

2025-12-31T00:00
Compound Assets Co.,Ltd.Juristic PersonReal Estate Development

• Joint shareholders

2025-12-31T00:00
BGI CollegeJuristic PersonEducational institutions provide training.

• Joint shareholders (shares held by BGI Shenzhen Co., Ltd.)

2025-12-31T00:00
BGI Specialized Medical solution DMCCJuristic PersonManufacture and distribution of protein products

• Joint shareholders

2025-12-31T00:00
BGI Precision Nutrition Trade Development (Shenzhen) Co., Ltd.Juristic PersonFood product import and export

• Joint shareholders

2025-12-31T00:00
Edge Medical (Thailand) Co., Ltd.Juristic PersonDistributor of medical equipment related to robotic surgery.

• Associate

2025-12-31T00:00

Transactions by Counterparty

Transactions
96.7 · Necessity: The Company purchases goods from BGI Health (HK), primarily reagents for laboratory services, which are standard catalog items. The purchase price for these goods is as stipulated in the contract, which is comparable to prices offered by BGI Health (HK) to other customers, taking into consideration market competition. · Description: The company procures products from BGI Health (HK), with the majority being reagents for laboratory services. · As of yesteryear: 80.93 · Nature of transaction: Purchase Products · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is as stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company. · As of year before yesteryear: 50.3 · 1.84 · Necessity: The Company clarifies that BGI Health (HK) is a service provider for analysis. In accordance with general business practices, the Company sends samples or DNA of its customers to BGI Health (HK) for analysis. The service fee is specified in the contract between the BGI Group and the Company. · Description: The company, namely BGI Health (HK), is under investigation. · As of yesteryear: 1.31 · Nature of transaction: Analysis Service Fee · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list is in accordance with general commercial practices. The service fees specified in the agreement between the BGI Group and the Company's subsidiaries are comparable to prices offered by BGI Health (HK) to other customers, taking into account market competition. This arrangement is beneficial and reasonable for the Company. · As of year before yesteryear: 0.99 · 68.36 · Necessity: The Company purchases goods from BGI Health (HK), primarily reagents for laboratory services, which are standard catalog items. The purchase price of such goods is the price stipulated in the contract, which is comparable to the price that BGI Health (HK) sells to other customers, taking into account market competition. · Description: The company procures products from BGI Health (HK), with the majority being reagents for laboratory services. · As of yesteryear: 18.62 · Nature of transaction: Trade creditor · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is as stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company. · As of year before yesteryear: 10.31 · 5.44 · Necessity: The company procured maintenance services (Warranty Sequencer) for equipment used within the laboratory. This procurement was conducted as a standard commercial transaction. The purchase price for these services aligns with the terms specified in the contract and is comparable to prices offered by BGI Health (HK) to other customers, taking into account market competition. · Description: The company purchased machine maintenance services (Warranty Sequencer). · As of yesteryear: 4.58 · Nature of transaction: Prepaid Expense · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is the price stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company. · As of year before yesteryear: 0.0 · 5.16 · Necessity: The company pays insurance premiums for the test result guarantee of NIFTY chromosomal analysis services to BGI Health (HK). These premiums are comparable to those charged by BGI Health (HK) to other customers, considering additional market competition factors. · Description: The company pays insurance premiums for the test result guarantee of NIFTY chromosomal analysis services to BGI Health (HK). · As of yesteryear: 6.21 · Nature of transaction: NIFTY PRO and NIFTY FOCUS Screening Test Costs & Insurance Coverage · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction is in line with normal commercial terms. The service fees are comparable to those charged by BGI Health (HK) to other customers, taking into account additional market competition. This allows the company to remain competitive with other service providers in Thailand, benefiting the company and ensuring reasonableness. · As of year before yesteryear: 5.8 · 5.26 · Necessity: The company procured maintenance services (Warranty Sequencer) for equipment used within the laboratory. This procurement was conducted as a standard commercial transaction. The purchase price for these services aligns with the terms specified in the contract and is comparable to prices offered by BGI Health (HK) to other customers, taking into account market competition · Description: The company purchased machine maintenance services (Warranty Sequencer). · As of yesteryear: 2.83 · Nature of transaction: Warranty Sequencer · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is the price stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company. · As of year before yesteryear: 0.0 · 2.95 · Necessity: The company purchases laboratory instruments and equipment from BGI Health (HK) for its business operations. The acquisition of these assets is conducted under standard commercial terms. · Description: The company purchases laboratory instruments and equipment from BGI Health (HK) for use in its business operations. · As of yesteryear: 3.0 · Nature of transaction: Purchased Assets · Audit committee opinion: The Audit Committee has reviewed and concluded that this transaction is in line with normal commercial terms. The purchase price of the assets is comparable to the price that BGI Health (HK) charges other customers, which benefits the company and is deemed reasonable. · As of year before yesteryear: 2.68 · 2.63 · Necessity: The company purchases laboratory instruments and equipment from BGI Health (HK) for use in its business operations. · Description: The Company has outstanding payables for asset acquisition from BGI Health (HK) for laboratory equipment to support operations and enhance laboratory efficiency. · As of yesteryear: 0.0 · Nature of transaction: Fixed Asset Payable · Audit committee opinion: The Audit Committee has reviewed and concluded that this transaction is in line with normal commercial terms. The purchase price of the assets is comparable to the price that BGI Health (HK) charges other customers, which benefits the company and is deemed reasonable. · As of year before yesteryear: 0.0 · 5.88 · Necessity: The Company acquired intangible assets from BGI Health (HK) as project development costs, with terms and conditions following general commercial practices · Description: The Company acquired intangible assets from BGI Health (HK) as project development costs · As of yesteryear: 0.0 · Nature of transaction: Purchased Intangible Assets · Audit committee opinion: The Audit Committee has reviewed and concluded that this transaction is in line with normal commercial terms. The purchase price of the assets is comparable to the price that BGI Health (HK) charges other customers, which benefits the company and is deemed reasonable. · As of year before yesteryear: 0.0 · 0.0 · Necessity: The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK) · Description: The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK). BGI Health (HK) sends test samples or DNA from its customers to the company. · As of yesteryear: 0.0 · Nature of transaction: Revenue from sales and services · Audit committee opinion: The Audit Committee has reviewed and opined that the transaction is in line with general commercial practices. The service rates are in accordance with the rates specified in the contract that the company provides to customers within the BGI group. · As of year before yesteryear: 2.69 · 0.0 · Necessity: The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK) · Description: The company provides chromosome screening services, specifically NIFTY Pro and NIFTY Focus, to BGI Health (HK). BGI Health (HK) sends test samples or DNA from its customers to the company. · As of yesteryear: 0.0 · Nature of transaction: Trade receivables · Audit committee opinion: .The Audit Committee has reviewed and opined that the transaction is in line with general commercial practices. The service rates are in accordance with the rates specified in the contract that the company provides to customers within the BGI group. · As of year before yesteryear: 0.05 · 0.01 · Necessity: The company has other revenue from BGI Health (HK), which is not derived from its core business and opined that the transaction is in line with general commercial practices. · Description: The company has other revenue from providing conference organizing services. In 2022, it received a donation of inventory following Thailand’s role as the host of the Asia-Pacific Economic Cooperation (APEC) conference in Q4 2022. During the conference, the BGI Group was exclusively appointed by the People's Republic of China as the COVID-19 testing provider for the delegates. After the conference, the BGI Group had leftover COVID-19 testing reagents from its operations and subsequently donated them to the company. · As of yesteryear: 0.29 · Nature of transaction: Other income · Audit committee opinion: The Audit Committee has reviewed and opined that the transaction is beneficial to the company and is reasonable. · As of year before yesteryear: 0.01 · 9.64 · Necessity: Other receivables from other income include insurance claim receivables. · Description: Other receivables arise from the company's conference organizing services and insurance claim receivables and opined that the transaction is in line with general commercial practices. · As of yesteryear: 8.57 · Nature of transaction: Other current receivable · Audit committee opinion: The Audit Committee has reviewed and opined that the transaction is beneficial to the company and is reasonable · As of year before yesteryear: 1.49
3.64 · Necessity: The company has contracted BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for studying genetic information, offering services to researchers involved in various projects. This is a transaction based on general trade practices, as it is a specialized service. The service price is determined based on the specifics of each project. The company uses a pricing policy for services provided to customers, calculating the price based on the total service cost plus a markup according to the company’s policy. · Description: The company has contracted BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for studying genetic information, offering services to researchers involved in various projects. · As of yesteryear: 2.89 · Nature of transaction: Technology Services · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction is in line with general business practices, with the pricing comparable to that of other clients served by BGI Tech Solutions (Hong Kong) Co., Ltd. The transaction is considered beneficial to the company and reasonable. · As of year before yesteryear: 3.36 · 0.43 · Necessity: The company has engaged BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for genetic information studies, offering these services to researchers in various projects. This transaction is in line with general business practices, as it involves a specialized service. The pricing for these services is determined based on the specifics of each project. The company follows a pricing policy that calculates the service cost by adding a markup to the total service cost, in accordance with the company’s profit margin policy. · Description: The company has engaged BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for the study of genetic information, in order to serve researchers involved in various projects. · As of yesteryear: 0.01 · Nature of transaction: Account Payables and Accrued expense · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction is in line with standard commercial practices, with pricing comparable to that charged by BGI Tech Solutions (Hong Kong) Co., Ltd. for services provided to other clients. This is considered beneficial to the company and reasonable. · As of year before yesteryear: 0.13 · 0.6 · Necessity: The company has engaged BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for the study of genetic data, which will support researchers in various projects. This transaction falls under standard commercial practices, as it is a specialized service. The pricing for these services is determined based on the specific details of each project. The company applies a pricing policy that calculates the service price based on the total service cost plus a markup percentage, in accordance with the company’s established pricing guidelines. · Description: The company has contracted BGI Tech Solutions (Hong Kong) Co., Ltd. to provide genetic testing services for the study of genetic data, aimed at supporting researchers in various projects. · As of yesteryear: 0.6 · Nature of transaction: Prepaid Expense · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that this transaction is in line with standard commercial practices, with pricing comparable to that charged by BGI Tech Solutions (Hong Kong) Co., Ltd. to other customers. This is deemed beneficial and reasonable for the company. · As of year before yesteryear: 0.0
0.0 · Necessity: The company provides DNALL analysis services to BGI Health (AU), where BGI Health (AU) sends samples or DNA from their clients to the company for analysis. The service rate for this is in accordance with the terms outlined in the contract between the company and other entities within the BGI group. · Description: The company provides DNALL analysis services to BGI Health (AU), where BGI Health (AU) sends samples or DNA from their clients to the company for analysis. · As of yesteryear: 0.05 · Nature of transaction: Service income · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the service provided is beneficial to the company and reasonable. Although the service rate is lower than the rate charged to external customers, the company still makes a profit. Additionally, gaining more clients will help enhance overall business growth. · As of year before yesteryear: 0.03
0.0 · Necessity: The Company purchases goods from Thai Omics Co., Ltd., including consumables such as films and microtiter plates used in the laboratory for PGT-A testing. These are standard commercial items. The purchase price of such goods is as specified in the contract, which is comparable to the price that Thai Omics Co., Ltd. sells to other customers, taking into account market competition. · Description: The company purchases goods from Thai Omics Co., Ltd., with products for PGT-A testing, which are common trade items. · As of yesteryear: 0.71 · Nature of transaction: Purchase Products · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the said list is in accordance with general commercial practices. The purchase price of such goods is the price stipulated in the contract and is comparable to the price at which BGI Health (HK) sells to other customers, taking into account additional market competition, which is beneficial and reasonable to the Company. · As of year before yesteryear: 0.03 · 0.31 · Necessity: The Company hired Thai Omics Co., Ltd. to provide genetic testing services to study genetic information. As this is a specialized service, the service fee is determined on a case-by-case basis depending on the specifics of each project. The Company will apply its service pricing policy to customers by calculating the total service cost plus a gross profit margin according to the Company's policy. · Description: The Company hired Thai Omics Co., Ltd. to provide genetic testing services to study genetic information. · As of yesteryear: 1.67 · Nature of transaction: Analysis Service Fee · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the item in question follows the general trade practices, with pricing in line with the company's policy. This is beneficial to the company and reasonable. · As of year before yesteryear: 0.44 · 0.03 · Necessity: The company has hired Thai Omics Co., Ltd. to provide genetic testing services for genetic data analysis. Since this is a specialized service, the pricing for such services depends on the specifics of each project. The company will apply its pricing policy by calculating the total service cost plus the gross profit margin, as per the company's policy. · Description: The company has engaged Thai Omics Co., Ltd. to provide genetic testing services for the study of genetic information. · As of yesteryear: 0.04 · Nature of transaction: Accounts Payable · Audit committee opinion: The audit committee has reviewed and concluded that the transaction is in line with general commercial practices, with the pricing being in accordance with the company's policies. It is beneficial to the company and reasonable. · As of year before yesteryear: 0.07 · 0.34 · Necessity: The transaction is conducted in the ordinary course of business to support group operations. The selling price and commercial terms are based on market prices or comparable to third-party transactions on an arm’s length basis. · Description: The Company generated revenue from the sale of reagent kits to Thai Omics Co., Ltd. · As of yesteryear: 0.0 · Nature of transaction: Revenue from Sales · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the transaction is reasonable and follows general commercial practices. The price and terms are consistent with third-party transactions. · As of year before yesteryear: 0.0 · 0.36 · Necessity: The transaction is conducted in the ordinary course of business to support group operations. The selling price and commercial terms are based on market prices or comparable to third-party transactions on an arm’s length basis. · Description: The Company has outstanding trade receivables from Thai Omics Co., Ltd., arising from the sale of diagnostic reagent kits in the ordinary course of business. · As of yesteryear: 0.0 · Nature of transaction: Trade Receivables · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the transaction is reasonable and follows general commercial practices. The price and terms are consistent with third-party transactions. · As of year before yesteryear: 0.0 · 106.5 · Necessity: The prepayment is a standard commercial term for made-to-order products to guarantee delivery and cover initial production costs, consistent with industry practices. · Description: The Company has outstanding prepayments to Thai Omics Co., Ltd. for the procurement of customized products, which require specific material sourcing and production lead time according to the Company's specifications. · As of yesteryear: 0.0 · Nature of transaction: Prepaid Expenses · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the transaction is necessary and reasonable to support business operations. The prepayment terms comply with general commercial practices, with close monitoring of production status and delivery to ensure the Company’s best interests. · As of year before yesteryear: 0.0
0.44 · Necessity: The company purchases goods from MGI Tech (Singapore), primarily laboratory equipment and consumables. These purchases are made under normal trade terms. · Description: The company procures goods from MGI Tech (Singapore), primarily laboratory equipment and reagents. · As of yesteryear: 6.8 · Nature of transaction: Purchase Products · Audit committee opinion: The Audit Committee has reviewed and opined that the transaction is considered to be in the ordinary course of business, with a price lower than that offered by other suppliers. Therefore, it is beneficial to the Company and deemed reasonable. · As of year before yesteryear: 0.14 · 2.05 · Necessity: The Company purchased machinery and laboratory equipment from MGI Tech Singapore Pte., Ltd. for use in the Company's operations. The purchase of such assets is subject to normal commercial terms. · Description: The company purchased laboratory equipment from MGI Tech (Singapore). · As of yesteryear: 6.26 · Nature of transaction: Asset Purchase · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list is in accordance with general commercial practices. The purchase price of such assets is comparable to the price at which MGI Tech Singapore Pte., Ltd. sells to other customers, which is beneficial and reasonable to the company. · As of year before yesteryear: 2.68 · 0.08 · Necessity: The company procured maintenance services for laboratory equipment from MGI Tech Singapore Pte., Ltd. The terms of the asset purchase agreement are in accordance with normal trade practices. · Description: The company procures maintenance services for laboratory equipment and devices from MGI Tech Singapore Pte., Ltd. · As of yesteryear: 0.04 · Nature of transaction: Service Charge · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list represents a general trade pricing structure. The purchase price of the assets is comparable to the price offered by MGI Tech Singapore Pte., Ltd. to other customers, which is deemed beneficial and reasonable for the company. · As of year before yesteryear: 0.0 · 0.14 · Necessity: The company procured maintenance services for laboratory equipment from MGI Tech Singapore Pte., Ltd. The terms of the asset purchase agreement are in accordance with normal trade practices. · Description: The company procures maintenance services for laboratory equipment and devices from MGI Tech Singapore Pte., Ltd. · As of yesteryear: 0.28 · Nature of transaction: Prepaid expense · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list represents a general trade pricing structure. The purchase price of the assets is comparable to the price offered by MGI Tech Singapore Pte., Ltd. to other customers, which is deemed beneficial and reasonable for the company. · As of year before yesteryear: 0.0
5.78 · Necessity: The Company leases office space from Krung Thai Tractor for its business operations. The rental rate is based on an appraisal by an independent appraiser approved by the Securities and Exchange Commission. This appraisal, conducted for public purposes, utilizes the Market Approach, comparing the rental rate to comparable market rates for similar properties in the vicinity. · Description: The company leases office space from Krung Thai Tractor for use in conducting its business. · As of yesteryear: 5.62 · Nature of transaction: Rental, Asset, Right of Use, and Building · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates. · As of year before yesteryear: 5.66 · 0.94 · Necessity: The Company paid utility expenses for the use of the office and premises to Krung Thai Tractor, whereby such expenses were based on actual costs incurred. · Description: The company pays utility expenses for the use of the office and premises to "Krung Thai Tractor". · As of yesteryear: 0.93 · Nature of transaction: Public utility costs · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates. · As of year before yesteryear: 0.93 · 0.03 · Necessity: The Company leases office space from Krung Thai Tractor for its business operations. The rental rate is based on an appraisal by an independent appraiser approved by the Securities and Exchange Commission. This appraisal, conducted for public purposes, utilizes the Market Approach, comparing the rental rate to comparable market rates for similar properties in the vicinity. · Description: The company leases office space from Krung Thai Tractor for use in conducting its business. · As of yesteryear: 0.02 · Nature of transaction: Others Accoutn Payable · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates. · As of year before yesteryear: 0.02 · 0.24 · Necessity: Deposits and guarantee deposits for leasing office space from Krungthai Tractor, used for the company's operations. · Description: Deposits and guarantee deposits for leasing office space from Krungthai Tractor, used for the company's operations. · As of yesteryear: 0.24 · Nature of transaction: Deposits and guarantees. · Audit committee opinion: The Audit Committee has reviewed and is of the opinion that the aforementioned list is beneficial to the company. The list aligns with general business practices, and the pricing is consistent with market rates. · As of year before yesteryear: 0.24
0.0 · Necessity: The company purchases goods from Shenzhen Zaozhidao Technology Co.,Ltd.., with most of the items being chemicals for research purposes. These purchases are made under normal commercial terms. · Description: The company purchases goods from Shenzhen Zaozhidao Technology Co.,Ltd.., with most of the items being chemicals for research purposes. · As of yesteryear: 1.19 · Nature of transaction: Purchase · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable. · As of year before yesteryear: 0.0 · 0.0 · Necessity: The company made a deposit payment for the purchase of goods from Shenzhen Zaozhidao Technology Co.,Ltd., with most of the items being chemicals for research purposes. The purchase was made under normal commercial terms. · Description: he company made a deposit payment for the purchase of goods from Shenzhen Zaozhidao Technology Co.,Ltd., with most of the items being chemicals for research purposes. · As of yesteryear: 0.24 · Nature of transaction: Deposit · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable. · As of year before yesteryear: 0.0
0.0 · Necessity: The company purchases goods from BGI Bio-Solutions Hongkong Co.,Ltd with most of the items being chemicals for research purposes. These purchases are made under normal commercial terms. · Description: The company purchases goods from BGI Bio-Solutions Hongkong Co.,Ltd with most of the items being chemicals for research purposes. · As of yesteryear: 0.01 · Nature of transaction: Purchase goods · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable. · As of year before yesteryear: 0.01 · 0.0 · Necessity: The company engaged BGI Bio Solutions Hongkong for genetic testing services to analyze genetic data and support researchers in various projects. This transaction follows normal commercial practices. As the service is highly specialized, pricing depends on the specific details of each project. The company sets its service pricing based on the total cost of service plus a gross profit margin in accordance with its pricing policy. · Description: The company engaged BGI Bio Solutions Hongkong for genetic testing services to analyze genetic data and support researchers in various projects. · As of yesteryear: 0.04 · Nature of transaction: Analysis Service Fee · Audit committee opinion: The Audit Committee has reviewed and concluded that the transaction follows normal commercial practices. The pricing is lower than other suppliers, benefiting the company and being reasonable. · As of year before yesteryear: 0.04

Policy & Future Trends

Policy, Measures & Approval Process

The company has established measures for conducting related party transactions within the group and with individuals who may have a conflict of interest. The Audit Committee is responsible for providing opinions on the necessity and reasonableness of such transactions, as well as the appropriateness of the pricing based on market conditions. These transactions should align with standard commercial practices and market prices, which can be compared with those offered to external parties. In cases where the Audit Committee lacks expertise in reviewing related party transactions, the company will seek advice from independent professionals with specialized knowledge, such as auditors, appraisers, or legal advisors, who are independent from the company and any conflicting parties. Their opinions will be used to assist the Audit Committee's decision-making, and the Committee will then present the matter to the Board of Directors or shareholders, as applicable.


In addition, the company has established measures to prevent executives or stakeholders from participating in the approval of transactions in which they have a direct or indirect interest. The Board of Directors is responsible for ensuring that the company complies with the Securities and Exchange Act and the regulations, announcements, orders, or requirements set by the Securities and Exchange Commission and the Stock Exchange of Thailand. This includes compliance with disclosure requirements for related party transactions and the acquisition or disposal of significant company assets, as well as adherence to accounting standards set by the Federation of Accounting Professions and licensed auditors in Thailand. The company will disclose related party transactions in the notes to the financial statements, which are audited or reviewed by the company's auditors.

Future Trends in Related Party Transactions

The company may engage in ongoing related party transactions in the future, which will follow the general nature of business practices. Clear policies will be established for such transactions, including prices and terms that are in line with standard business practices, similar to those set with unrelated parties, such as the purchase or sale of goods, the provision or receipt of services, and property leasing. These related party transactions will be necessary for the company's operations and will benefit the company. The Audit Committee will review and assess compliance with these guidelines and provide opinions on the reasonableness of the transactions on a quarterly basis.


For related party transactions that are not in the ordinary course of business and may occur in the future, the company will ensure that the Audit Committee reviews compliance with the relevant criteria and provides justifications for the transaction before the company and its subsidiaries enter into such transactions. The Audit Committee will offer opinions on the necessity, reasonableness, and appropriateness of the pricing of the transaction, considering various conditions to ensure it aligns with standard commercial practices and market prices, which can be compared to those offered to external parties. In cases where the Audit Committee lacks expertise in reviewing potential related party transactions, the company will seek advice from independent experts, such as auditors, appraisers, or legal advisors, who are independent from the company group and any conflicting parties. Their opinions will assist the Audit Committee in its decision-making, which will then be presented to the Board of Directors or shareholders, as applicable. The company will follow the measures and approval procedures for related party transactions as outlined above. However, for related party transactions that could potentially lead to conflicts of interest in the future, the Board of Directors must ensure compliance with the Securities and Exchange Act, regulations, announcements, orders, or requirements from the Securities and Exchange Commission and the Stock Exchange of Thailand. This also includes compliance with disclosure requirements for related party transactions and the acquisition or disposal of assets within the company group or its subsidiaries, as well as adherence to accounting standards set by the Federation of Accounting Professions and licensed auditors in Thailand.

Contents